Updates On Relapsing-Remitting Multiple Sclerosis

Isaura Santos avatar

by Isaura Santos |

Share this article:

Share article via email

news-38

Genzyme, a Sanofi company, recently announced novel positive 5-year experimental data from the extension study of Lemtrada® (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS).

Read the findings here: http://bit.ly/1LEWNQV

Print This Page

About the Author

Isaura Santos avatar
Isaura Santos Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

Tags

ECTRIMS 2015, relapsing remitting multiple sclerosis

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Video

Recent Posts

Recommended reading